Aspira Womens Health (Aspira Womens Health) Cash-to-Debt

: 0.91 (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Aspira Womens Health's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.91.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Aspira Womens Health couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Aspira Womens Health's Cash-to-Debt or its related term are showing as below:

AWH' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.91 Med: 4.9 Max: No Debt
Current: 0.91

During the past 13 years, Aspira Womens Health's highest Cash to Debt Ratio was No Debt. The lowest was 0.91. And the median was 4.90.

AWH's Cash-to-Debt is ranked worse than
57.26% of 234 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.45 vs AWH: 0.91

Aspira Womens Health Cash-to-Debt Historical Data

The historical data trend for Aspira Womens Health's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Aspira Womens Health Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

7.11

3.22

9.05

3.47

0.91

Aspira Womens Health Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															3.47	2.14	1.83	2.18	0.91

Competitive Comparison

For the Diagnostics & Research subindustry, Aspira Womens Health's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aspira Womens Health Cash-to-Debt Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Aspira Womens Health's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Aspira Womens Health's Cash-to-Debt falls into.

Aspira Womens Health Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Aspira Womens Health's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	2.597	/	(0.995	+	1.857)
	=	0.91

Aspira Womens Health's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	2.597	/	(0.995	+	1.857)
	=	0.91

Aspira Womens Health (NAS:AWH) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Aspira Womens Health Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Aspira Womens Health's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Aspira Womens Health (Aspira Womens Health) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Aspira Womens Health Inc (NAS:AWH) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

12117 Bee Caves Road, Suite 100, Building 3, Austin, TX, USA, 78738

Website

https://www.aspirawh.com

Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. The Company markets and sells, 1) Ova1, a blood test intended as an aid to assess the likelihood of malignancy in women with an ovarian adnexal mass for which surgery is planned when the physician's independent clinical and radiological evaluation does not indicate malignancy; (2) Overa, a second-generation biomarker reflex intended to maintain Ova1's high sensitivity while improving specificity; (3) Ova1Plus, a reflex offering which uses Ova1 as the primary test and Overa as a confirmation for Ova1 intermediate range results; and (4) OvaWatch, a lab-developed blood test intended to assist in the initial clinical assessment of malignancy risk in all women with an adnexal mass.

Executives

Nicole Sandford	director	12117 BEE CAVES RD BLDG 3, STE 100, AUSTIN TX 78738
Minh Hoang Merchant	officer: General Counsel & Secretary	1210 AVONDALE ROAD, HILLSBOROUGH CA 94010
Torsten Hombeck	officer: Chief Financial Officer	529 W 42ND ST #6V, NEW YORK NY 10036
Celeste Rachelle Fralick	director	2801 MESA ROAD, LUBBOCK TX 79403
Veronica Gh Jordan	director	C/O ALBANY MOLECULAR RESEARCH, INC., 26 CORPORATE CIRCLE, ALBANY NY 12212-5098
Stefanie L. Cavanaugh	director	1120 S CAPITAL OF TX HWY, BLDG 1, STE 300, AUSTIN TX 78746
Ellen O'connor Vos	director	C/O NTELOS HOLDINGS CORP., 1154 SHENANDOAH VILLAGE DRIVE, WAYNESBORO VA 22980
Jack W Schuler	10 percent owner	100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Ryan Thinh Phan	officer: CSO & COO	327 CARLTON AVE, LOS GATOS CA 95032
Jannie Prestridge Herchuk	director	6331 LAVENDALE AVE, DALLAS TX 75230
Winfred Parnell	director	6734 TALMADGE LANE, DALLAS TX 75230
Marlene Mclennan	officer: Interim Chief Financial Office	400 SOUTH AUSTRALIAN AVENUE, SUITE 800, WEST PALM BEACH FL 33401
Ruby Sharma	director	24 ARNOLD DRIVE, PRINCETON JCT. NJ 08550
Robert D Auerbach	director	C/O THE COOPER COMPANIES, INC., SUITE 590, PLEASANTON CA 94588
Valerie Barber Palmieri	director, officer: President and CEO	63 INDIAN LEDGE RD., MONROE CT 06468